We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hin Die...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer Findings Show Trends for Reduced Toxicities and Better...
XBiotech beginnt mit dem Bau der neuen F&E-Anlage auf seinem 19 Hektar großen Campus AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. gab heute sein Vorhaben bekannt...
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus...
Le Dr Alan Kivitz prend la tête du programme Natrunix, conduit par XBiotech dans le traitement de la polyarthrite rhumatoïde (L’étude clinique multicentrique de phase II progresse bien et...
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis (Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.35 | -4.96453900709 | 7.05 | 7.35 | 6.7 | 205 | 7.05406504 | DE |
4 | -0.1 | -1.47058823529 | 6.8 | 7.5 | 6.65 | 500 | 6.93178866 | DE |
12 | 0.6 | 9.83606557377 | 6.1 | 7.5 | 5.9 | 412 | 6.68349525 | DE |
26 | 0.1 | 1.51515151515 | 6.6 | 7.5 | 4.0599999 | 500 | 6.00544733 | DE |
52 | 3.04 | 83.0601092896 | 3.66 | 9.05 | 3.52 | 587 | 5.75121755 | DE |
156 | 2.08 | 45.0216450216 | 4.62 | 9.05 | 3.32 | 576 | 5.60787167 | DE |
260 | 2.08 | 45.0216450216 | 4.62 | 9.05 | 3.32 | 576 | 5.60787167 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions